UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000030237
Receipt number R000034537
Scientific Title Additional postoperative intravenous tranexamic acid administration versus placebo administration for patients treated with intraoperative combined intravenous and intra-articular tranexamic acid in total knee arthroplasty: a randomized, double-blind, placebo-controlled trial
Date of disclosure of the study information 2017/12/03
Last modified on 2020/02/15 15:16:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Additional postoperative intravenous tranexamic acid administration versus placebo administration for patients treated with intraoperative combined intravenous and intra-articular tranexamic acid in total knee arthroplasty: a randomized, double-blind, placebo-controlled trial

Acronym

Additional postoperative intravenous tranexamic acid administration versus placebo in total knee arthroplasty

Scientific Title

Additional postoperative intravenous tranexamic acid administration versus placebo administration for patients treated with intraoperative combined intravenous and intra-articular tranexamic acid in total knee arthroplasty: a randomized, double-blind, placebo-controlled trial

Scientific Title:Acronym

Additional postoperative intravenous tranexamic acid administration versus placebo in total knee arthroplasty

Region

Japan


Condition

Condition

Osteoarthritis of the knee, rheumatoid arthritis, avascular necrosis

Classification by specialty

Orthopedics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate whether postoperative intravenous tranexamic acid administration can reduce blood loss after total knee arthroplasty compared with postoperative normal saline administration in patients treated with intraoperative combined intravenous and intra-articular tranexamic acid administration.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The volume of perioperative blood loss measured using the calculated blood volume and change in hemoglobin from preoperative to postoperative day 3

Key secondary outcomes

1. The volume of perioperative blood loss measured using the calculated blood volume and change in hemoglobin from preoperative to postoperative day 7
2. Range of knee motion
3. Complication


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking

NO

Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Additional postoperative intravenous tranexamic acid group: Patients received 1000 mg of tranexamic acid administered intravenously just before skin incision and 1000 mg of tranexamic acid administered intra-articularly after closure of the capsule and retinaculum. In addition, patients received 1000mg/100mL of tranexamic acid administered intravenously 6 hours after the first intravenous administration of tranexamic acid, and 08:00 and 20:00 one day after surgery.

Interventions/Control_2

Placebo group: Patients received 1000 mg of tranexamic acid administered intravenously just before skin incision and 1000 mg of tranexamic acid administered intra-articularly after closure of the capsule and retinaculum. Patients received 100 mL of normal saline administered intravenously 6 hours after the first intravenous administration of tranexamic acid, and 08:00 and 20:00 one day after surgery.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients undergoing unilateral total knee arthroplasty

Key exclusion criteria

Known allergic reaction to tranexamic acid

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Sachiyuki Tsukada

Organization

Hokusuikai Kinen Hospital

Division name

Orthopaedic Surgery

Zip code


Address

Higashihara 3-2-1, Mito, Ibaraki, Japan

TEL

0293033003

Email

s8058@nms.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Sachiyuki Tsukada

Organization

Hokusuikai Kinen Hospital

Division name

Orthopaedic Surgery

Zip code


Address

Higashihara 3-2-1, Mito, Ibaraki, Japan

TEL

0293033003

Homepage URL


Email

s8058@nms.ac.jp


Sponsor or person

Institute

Hokusuikai Kinen Hospital

Institute

Department

Personal name



Funding Source

Organization

Hokusuikai Kinen Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 12 Month 03 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

https://journals.lww.com/jbjsjournal/pages/articleviewer.aspx?year=9000&issue=00000&article=99839&ty

Number of participants that the trial has enrolled

100

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 09 Month 21 Day

Date of IRB


Anticipated trial start date

2018 Year 01 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 12 Month 03 Day

Last modified on

2020 Year 02 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034537


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name